BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Trius Antibiotic Tedizolid Hits Phase III Endpoints vs. Zyvox
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Trius Antibiotic Tedizolid Hits Phase III Endpoints vs. Zyvox
Dec. 20, 2011
By
Trista Morrison
No Comments
Trius Therapeutics Inc. hit all primary and secondary endpoints in its first Phase III trial of antibiotic tedizolid (formerly torezolid), yet investors rewarded the San Diego biotech by pushing its shares down 12 percent.
BioWorld